Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 34 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKIActive, not recruitingNCT05920135Phase 1/2
• Abequolixron (RGX-104) and Durvalumab in Lung CancerTerminatedNCT05911308Phase 1
• Emulation of the KEYNOTE-189 Trial Using Electronic Health RecordsCompletedNCT05908799
• A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05908734Phase 1/2
• A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsActive, not recruitingNCT05907304Phase 1
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsActive, not recruitingNCT05899608Phase 3
• TEIPP Immunotherapy in Patients With NSCLCCompletedNCT05898763Phase 1/2
• Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLCActive, not recruitingNCT05894889Phase 2
• A Biomarker Screening Protocol for Participants With Solid TumorsTerminatedNCT05891197
• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive, not recruitingNCT05891171Phase 1
• Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsActive, not recruitingNCT05887492Phase 1/2
• CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in RussiaActive, not recruitingNCT05887011
• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2
• Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung CancerActive, not recruitingNCT05882513Phase 2
• A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05880706Phase 2
• A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersActive, not recruitingNCT05873686Phase 1
• Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLCCompletedNCT05873439Early Phase 1
• A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With SurgeryCompletedNCT05872763
• A Phase III Study of SKB264 for EGFR Mutant NSCLC PatientsActive, not recruitingNCT05870319Phase 3
• A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010CompletedNCT05867121Phase 1
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsCompletedNCT05864144Phase 1/2
• Analyzing Clinical Outcomes and Genomic Data of American Indian Patient PopulationActive, not recruitingNCT05863052
• Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLCCompletedNCT05862194
• A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced MalignanciesTerminatedNCT05861947Phase 1
• A Study of [14C]GB491 in Male Healthy SubjectsCompletedNCT05860582Phase 1
• Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung CancersTerminatedNCT05860296Phase 1/2
• To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.Status unknownNCT05859373Phase 1/2
• Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsCompletedNCT05858736Phase 1
• A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid TumorsCompletedNCT05858164Phase 1
• Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Active, not recruitingNCT05853575Phase 2
• The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)TerminatedNCT05849246Phase 2
• Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET AlterationsActive, not recruitingNCT05845671Phase 1/2
• Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung CancerWithdrawnNCT05840770Phase 2
• AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05840016Phase 3
• Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompletedNCT05826366
• NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKingActive, not recruitingNCT05825625Phase 2
• Digital Lifestyle Intervention for Lung Cancer SurvivorsCompletedNCT05819346Not applicable
• Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)Active, not recruitingNCT05818449Not applicable
• Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05816499Phase 1/2
• A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Active, not recruitingNCT05816252Phase 2
• Expressiona and Diagnostic Potential of miRNAs in NSCLCCompletedNCT05815407
• Ladarixin With Sotorasib in Advanced NSCLC - Phase IIWithdrawnNCT05815186Phase 2
• Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC PatientsTerminatedNCT05812274Not applicable
• A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid TumorsActive, not recruitingNCT05812027
• Quest for Tumour Evolution of Non-small Cell Lung CancerActive, not recruitingNCT05811169
• Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA ProfilesCompletedNCT05810350Phase 2
• Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain MetastasesCompletedNCT05807893Phase 2/3
• To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLCCompletedNCT05805267
• Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT05801107Phase 2
• A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsActive, not recruitingNCT05801029Phase 2
• Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male VolunteersCompletedNCT05800418Phase 1
• A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerActive, not recruitingNCT05800015Phase 2/3
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsActive, not recruitingNCT05799274Phase 1
• Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 MutationsCompletedNCT05796726
• Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T LymphocytesCompletedNCT05792995Phase 2
• Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.WithdrawnNCT05791097Phase 3
• A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05789069Phase 1
• A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)TerminatedNCT05788926Phase 1
• A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC PatientsActive, not recruitingNCT05787613Phase 2
• Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior LazertinibCompletedNCT05786430Phase 2
• Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung CancerCompletedNCT05785845Not applicable
• Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.Status unknownNCT05785208Phase 4
• Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)Active, not recruitingNCT05784142Phase 2
• Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT05783622Phase 1
• POTENT - Tepotinib in Combination With Pembrolizumab in NSCLCActive, not recruitingNCT05782361Phase 1
• Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & ChemotherapyActive, not recruitingNCT05781308Phase 2
• Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)CompletedNCT05775796Phase 2
• Study of RO7515629 in Participants With HLA-G Positive Solid TumorsTerminatedNCT05769959Phase 1
• A Study of Prevalence of HER3 Expression in Non-Small Cell Lung CancerCompletedNCT05769764
• Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC PatientsCompletedNCT05758116Phase 2
• A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLCActive, not recruitingNCT05756972Phase 2
• A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced MalignanciesCompletedNCT05753722Phase 1
• Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer PatientsStatus unknownNCT05746598
• A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05741021Phase 2
• Induction Lorlatinib in Stage III Non-small Cell Lung CancerActive, not recruitingNCT05740943Phase 2
• Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung CancerCompletedNCT05740501
• Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced MalignanciesActive, not recruitingNCT05739006Phase 1
• Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line TreatmentStatus unknownNCT05738317Phase 2
• Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationTerminatedNCT05737706Phase 1
• Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain MetastasisStatus unknownNCT05737589
• A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionActive, not recruitingNCT05736731Phase 1/2
• A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETYActive, not recruitingNCT05735327
• Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLCStatus unknownNCT05725915
• A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)Active, not recruitingNCT05721950
• Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation TherapyActive, not recruitingNCT05717998
• Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyTerminatedNCT05715229Phase 2
• Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruitingNCT05712902Phase 2
• Predicting Response to PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging and Clinical DataCompletedNCT05711914
• A Study to Compare Tissue and Liquid Biopsies in People With Different Types of CancerActive, not recruitingNCT05708599Not applicable
• Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung CancerWithdrawnNCT05705466Phase 1/2
• Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving ImmunotherapyActive, not recruitingNCT05703269Not applicable
• Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerWithdrawnNCT05693090Phase 1
• Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STSActive, not recruitingNCT05688280Phase 1/2
• Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly PatientsCompletedNCT05688046
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05687266Phase 3
• C-TIL051 in Non-Small Cell Lung CancerTerminatedNCT05676749Phase 1
• Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance StatusActive, not recruitingNCT05673187Phase 2
• ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsActive, not recruitingNCT05671510Phase 3
• A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingNCT05668988Phase 3

← Carcinoma, Non-Small-Cell Lung overview